Global Hypercholesterolemia Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025

  • ID: 4431600
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Aegerion Pharmaceuticals
  • Amgen Inc.
  • AstraZeneca
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • MORE
Hypercholesterolemia Drugs Market - Growth, Future Prospects and Competitive Analysis, 2017 - 2025 the global hypercholesterolemia drugs market, expanding at a CAGR of 5.6% from 2017 to 2025.

Market Insights

Hypercholesterolemia also known as high cholesterol, is the presence of excess levels of cholesterol in the body that increases a risk of developing heart attack, and stroke. Changes in lifestyle pattern such as the adoption of a sedentary form, increasing rate alcohol consumption and change in dietary pattern are driving the growth of hypercholesterolemia drugs market. For the purpose of the study hypercholesterolemia drugs market is segmented on the basis of drug class such as HMG-CoA reductase inhibitors/ statins, bile acid sequestrants, fibrates, cholesterol absorption inhibitors, others drugs. It is studied that, currently HMG-CoA reductase inhibitors/ statins held largest market share because statins are commonly prescribed drug class due to their safety and effectiveness in lowering cholesterol. In the base year 2016, North America dominated the global hypercholesterolemia drugs market due to the large number of target population, rise in geriatric population, increase in number of obese population with increase in risk of cardiovascular disease are prime contributors in North America. On the other hand, Asia Pacific will grow significantly during forecast period due to changing lifestyle and growing healthcare awareness that would assist the growth of hypercholesterolemia drugs market.

Market Competition Assessment

The hypercholesterolemia drugs market is observed to be highly competitive and comprises large number of players. However, the market is currently dominated by few players such as AbbVie Inc., Aegerion Pharmaceuticals, Amgen Inc., AstraZeneca, Eli Lilly and Company, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Shore Therapeutics, Inc., Teva Pharmaceuticals and other.

Key Market Movements:
  • Some factors such as increase in number of obese population, growing geriatric population, rising healthcare awareness and growing incidence of cardiovascular disease are primarily driving the growth of hypercholesterolemia drugs market globally.
  • Promising pipeline molecules, rising incidence of hypercholesterolemia and changing lifestyle pattern is expected to assist market growth during forecast period.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Aegerion Pharmaceuticals
  • Amgen Inc.
  • AstraZeneca
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • MORE
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I - Secondary Research
1.3.2 Phase II - Primary Research
1.3.3 Phase III - Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Hypercholesterolemia Drugs Market Snapshot
2.2 Global Hypercholesterolemia Drugs Market, by Drugs Class
2.3 Global Hypercholesterolemia Drugs Market Share, by Geography, 2016 (Value %)

Chapter 3 Hypercholesterolemia Drugs Market Analysis
3.1 Global Hypercholesterolemia Drugs Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Pipeline Analysis of Hypercholesterolemia Drugs
3.4 Guidelines for Management of Hypercholesterolemia
3.5 Attractive Investment Proposition
3.6 Competitive Landscape of Key Players in Hypercholesterolemia Drugs Market

Chapter 4 Global Hypercholesterolemia Drugs Market, by Drugs Class
4.1 Overview
4.2 Attractive Investment Proposition: Global Hypercholesterolemia Drugs Market, by Drugs Class
4.3 Top 3 Countries
4.4 HMG-CoA Reductase Inhibitors/ Statins
4.5 Bile Acid Sequestrants
4.6 Fibrates
4.7 Cholesterol Absorption Inhibitors
4.8 Other

Chapter 5 Global Hypercholesterolemia Drugs Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.2.1 North America Hypercholesterolemia Drugs Market, by Drugs Class, 2015- 2025 (US$)
5.2.2 North America Hypercholesterolemia Drugs Market, by Country, 2015- 2025 (US$)
5.3 Europe (U.K., Germany & Rest of Europe)
5.3.1 Europe Hypercholesterolemia Drugs Market, by Drugs Class, 2015- 2025 (US$)
5.3.2 Europe Hypercholesterolemia Drugs Market, by Country, 2015- 2025 (US$)
5.4 Asia Pacific (China, Japan and Rest of APAC)
5.4.1 Asia Pacific Hypercholesterolemia Drugs Market, by Drugs Class, 2015- 2025 (US$)
5.4.1 Asia Pacific Hypercholesterolemia Drugs Market, by Country, 2015- 2025 (US$)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.5.1 Latin America Hypercholesterolemia Drugs Market, by Drugs Class, 2015- 2025 (US$)
5.5.2 Latin America Hypercholesterolemia Drugs Market, by Country, 2015- 2025 (US$)
5.6 Middle East and Africa (GCC and Rest of MEA)
5.6.1 Middle East and Africa Hypercholesterolemia Drugs Market, by Drugs Class, 2015- 2025 (US$)
5.6.2 Middle East and Africa Hypercholesterolemia Drugs Market, by Country, 2015- 2025 (US$)

Chapter 6 Company Profiles
6.1 AbbVie Inc.
6.2 Aegerion Pharmaceuticals
6.3 Amgen Inc.
6.4 AstraZeneca
6.5 Eli Lilly and Company
6.6 Lupin Pharmaceuticals, Inc.
6.7 Merck & Co., Inc.
6.8 Pfizer Inc.
6.9 Sanofi S.A.
6.10 Shore Therapeutics, Inc.
6.11 Teva Pharmaceuticals

List of Figures
Fig. 1 Hypercholesterolemia Drugs Market: Research Methodology
Fig. 2 Global Hypercholesterolemia Drugs Market, by Drugs Class, 2016 (US$ Bn)
Fig. 3 Global Hypercholesterolemia Drugs Market Share, by Geography, 2016 (Value %)
Fig. 4 Attractive Investment Proposition: Global Hypercholesterolemia Drugs Market, by Geography, 2016
Fig. 5 Attractive Investment Proposition: Global Hypercholesterolemia Drugs Market, by Drugs Class, 2016
Fig. 6 Global Hypercholesterolemia Drugs Market for HMG-CoA Reductase Inhibitors/ Statins, 2015 - 2025 (US$ Bn)
Fig. 7 Global Hypercholesterolemia Drugs Market for Bile Acid Sequestrants, 2015 - 2025 (US$ Bn)
Fig. 8 Global Hypercholesterolemia Drugs Market for Fibrates, 2015 - 2025 (US$ Bn)
Fig. 9 Global Hypercholesterolemia Drugs Market for Cholesterol Absorption Inhibitors, 2015 - 2025 (US$ Bn)
Fig. 10 Global Other Drugs in Hypercholesterolemia Drugs Market, 2015 - 2025 (US$ Bn)

List of Tables
Table 1 Market Positioning of Key Players in Global Hypercholesterolemia Drugs Market
Table 2 Global Hypercholesterolemia Drugs Market, by Drugs Class, 2015 - 2025 (US$ Bn)
Table 3 Top 3 Countries in Global Hypercholesterolemia Drugs Market, by Drugs Class 2015 - 2025 (US$ Bn)
Table 4 Global Hypercholesterolemia Drugs Market, by Geography, 2015 - 2025 (US$ Bn)
Table 5 North America Hypercholesterolemia Drugs Market, by Drugs Class, 2015-2025 (US$ Bn)
Table 6 North America Hypercholesterolemia Drugs Market, by Country, 2015 - 2025 (US$ Bn)
Table 7 Europe Hypercholesterolemia Drugs Market, by Drugs Class, 2015-2025 (US$ Bn)
Table 8 Europe Hypercholesterolemia Drugs Market, by Country, 2015 - 2025 (US$ Bn)
Table 9 Asia Pacific Hypercholesterolemia Drugs Market, by Drugs Class, 2015-2025 (US$ Bn)
Table 10 Asia Pacific Hypercholesterolemia Drugs Market, by Country, 2015 - 2025 (US$ Bn)
Table 11 Latin America Hypercholesterolemia Drugs Market, by Drugs Class, 2015-2025 (US$ Bn)
Table 12 Latin America Hypercholesterolemia Drugs Market, by Country, 2015 - 2025 (US$ Bn)
Table 13 Middle East and Africa Hypercholesterolemia Drugs Market, by Drugs Class, 2015-2025 (US$ Bn)
Table 14 Middle East and Africa Hypercholesterolemia Drugs Market, by Country, 2015 - 2025 (US$ Bn)
Table 15 AbbVie Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 16 Aegerion Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 17 Amgen Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 18 AstraZeneca: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 19 Eli Lilly and Company: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 20 Lupin Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 21 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 22 Pfizer Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 23 Sanofi S.A.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 24 Shore Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 25 Teva Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie Inc.
  • Aegerion Pharmaceuticals
  • Amgen Inc.
  • AstraZeneca
  • Eli Lilly and Company
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Shore Therapeutics, Inc.
  • Teva Pharmaceuticals
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll